Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.
A panel of experts shares key insights into the role of photopheresis when patients with GVHD progress following initial treatment and emphasize its potential for patients with high skin involvement.
Key opinion leaders in stem cell transplant and cellular immunotherapy review therapeutic considerations for the clinical scenario of a patient with steroid-refractory chronic GVHD.
Investigators observed low enrollment of Black patients on CAR T-cell therapy clinical trials that supported FDA decisions in hematologic malignancies, especially in multiple myeloma.
Panelists consider the importance of studying trial drugs in a blinded, randomized fashion to mitigate physician and patient bias regarding patient-reported outcomes for GVHD therapies.
John F. DiPersio, MD, PhD, presents the clinical scenario of a 71-year-old patient postmatched unrelated donor HSCT, and the panel discusses first- and second-line treatment approaches including topical and systemic therapies.
Patients with chronic graft-vs-host disease who were administered full series of the SARS-CoV-2 vaccine displayed varied immune responses, regardless of baseline characteristics.
Patients with hematologic cancer experienced a low incidence of chronic graft-versus-host disease after receiving a regimen consisting of myeloablative hematopoietic cell transplantation and total body irradiation plus prophylactic post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.
In the phase 1b EQUATE trial, patients with acute graft-versus-host disease had decreased levels of cell-surface CD6 when treated with itolizumab.